Clinical Trial Update: AVELUMAB and CETUXIMAB and mFOLFOXIRI as Initial Therapy for Unresectable Metastatic Colorectal Cancer Patients [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating avelumab plus cetuximab and mFOLFOXIRI as initial therapy for unresectable metastatic colorectal cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• 5-FU (5-fluorouracil)
• BAVENCIO (AVELUMAB)
• ERBITUX (cetuximab)
• Irinotecan (Irinotecan)
• Leucovorin (folinic acid)
• OXALIPLATIN (Oxaliplatin)

Snippet

Sponsor: Gruppo Oncologico del Nord-Ovest | Conditions: Metastatic Colorectal Cancer | Phase 2 | Status: COMPLETED